{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:10:37Z","timestamp":1791202237536,"version":"4.2.0"},"reference-count":50,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,10,13]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mantle cell lymphoma (MCL) usually responds well to initial therapy but is prone to relapses with chemoresistant disease, indicating the need for novel therapeutic approaches. Inhibition of the p53 E3 ligase human homolog of the murine double minute protein-2 (HDM-2) with MI-63 has been validated as one such strategy in wild-type (wt) p53 models, and our genomic and proteomic analyses demonstrated that MI-63 suppressed the expression of the ribonucleotide reductase (RNR) subunit M2 (RRM2). This effect occurred in association with induction of p21 and cell-cycle arrest at G1\/S and prompted us to examine combinations with the RNR inhibitor 2\u2032,2\u2032-difluoro-2\u2032-deoxycytidine (gemcitabine). The regimen of MI-63\u2013gemcitabine induced enhanced, synergistic antiproliferative, and proapoptotic effects in wtp53 MCL cell lines. Addition of exogenous dNTPs reversed this effect, whereas shRNA-mediated inhibition of RRM2 was sufficient to induce synergy with gemcitabine. Combination therapy of MCL murine xenografts with gemcitabine and MI-219, the in vivo analog of MI-63, resulted in enhanced antitumor activity. Finally, synergy was seen with MI-63\u2013gemcitabine in primary patient samples that were found to express high levels of RRM2 compared with MCL cell lines. These findings provide a framework for translation of the rational combination of an HDM-2 and RNR inhibitor to the clinic for patients with relapsed wtp53 MCL.<\/jats:p>","DOI":"10.1182\/blood-2011-03-340323","type":"journal-article","created":{"date-parts":[[2011,8,16]],"date-time":"2011-08-16T01:02:36Z","timestamp":1313456556000},"page":"4140-4149","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":33,"title":["HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma"],"prefix":"10.1182","volume":"118","author":[{"given":"Richard J.","family":"Jones","sequence":"first","affiliation":[{"name":"Department of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerabhadran","family":"Baladandayuthapani","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sattva","family":"Neelapu","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis E.","family":"Fayad","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Romaguera","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dajun","family":"Yang","sequence":"additional","affiliation":[{"name":"Ascenta Therapeutics Inc, Malvern, PA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX;"},{"name":"Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2019111809151810300_B1","first-page":"115","article-title":"Mantle-cell lymphoma.","volume":"36","author":"Campo","year":"1999","journal-title":"Semin Hematol"},{"issue":"7","key":"2019111809151810300_B2","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1517\/14728222.11.7.929","article-title":"Novel therapeutic targets in mantle cell lymphoma.","volume":"11","author":"Martin","year":"2007","journal-title":"Expert Opin Ther Targets"},{"key":"2019111809151810300_B3","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1182\/asheducation-2007.1.270","article-title":"Mantle cell lymphoma: identifying novel molecular targets in growth and survival pathways.","volume":"2007","author":"O'Connor","year":"2007","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"22","key":"2019111809151810300_B4","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1200\/JCO.2002.01.133","article-title":"Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.","volume":"20","author":"Orlowski","year":"2002","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111809151810300_B5","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.","volume":"23","author":"O'Connor","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111809151810300_B6","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.","volume":"23","author":"Goy","year":"2005","journal-title":"J Clin Oncol"},{"issue":"30","key":"2019111809151810300_B7","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"issue":"23","key":"2019111809151810300_B8","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111809151810300_B9","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/leu.2010.226","article-title":"A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma.","volume":"25","author":"Witzig","year":"2011","journal-title":"Leukemia"},{"issue":"30","key":"2019111809151810300_B10","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","article-title":"Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.","volume":"26","author":"Wiernik","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111809151810300_B11","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","article-title":"Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.","volume":"145","author":"Habermann","year":"2009","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111809151810300_B12","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1046\/j.1365-2141.2001.02795.x","article-title":"Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma.","volume":"113","author":"Dumontet","year":"2001","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111809151810300_B13","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/hon.891","article-title":"A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36\/03.","volume":"27","author":"Hitz","year":"2009","journal-title":"Hematol Oncol"},{"issue":"2","key":"2019111809151810300_B14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3816\/CLM.2002.n.015","article-title":"Gemcitabine and its combinations in the treatment of malignant lymphoma.","volume":"3","author":"Chau","year":"2002","journal-title":"Clin Lymphoma"},{"key":"2019111809151810300_B15","first-page":"11","article-title":"Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism.","volume":"22","author":"Heinemann","year":"1995","journal-title":"Semin Oncol"},{"issue":"22","key":"2019111809151810300_B16","first-page":"6110","article-title":"Action of 2\u2032,2\u2032-difluorodeoxycytidine on DNA synthesis.","volume":"51","author":"Huang","year":"1991","journal-title":"Cancer Res"},{"issue":"4","key":"2019111809151810300_B17","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0026-895X(25)09518-5","article-title":"Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2\u2032,2\u2032-difluorodeoxycytidine.","volume":"38","author":"Heinemann","year":"1990","journal-title":"Mol Pharmacol"},{"issue":"6","key":"2019111809151810300_B18","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1021\/jm00110a019","article-title":"2\u2032-Deoxy-2\u2032-methylenecytidine and 2\u2032-deoxy-2\u2032,2\u2032-difluorocytidine 5\u2032-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase.","volume":"34","author":"Baker","year":"1991","journal-title":"J Med Chem"},{"issue":"17","key":"2019111809151810300_B19","first-page":"4204","article-title":"Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line.","volume":"59","author":"Goan","year":"1999","journal-title":"Cancer Res"},{"issue":"5","key":"2019111809151810300_B20","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2174\/156800906777723949","article-title":"Ribonucleotide reductase inhibitors and future drug design.","volume":"6","author":"Shao","year":"2006","journal-title":"Curr Cancer Drug Targets"},{"issue":"2","key":"2019111809151810300_B21","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2141.2008.07124.x","article-title":"Advances in the understanding of mantle cell lymphoma.","volume":"142","author":"Jares","year":"2008","journal-title":"Br J Haematol"},{"issue":"9","key":"2019111809151810300_B22","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.3109\/10428194.2010.496507","article-title":"Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network conference.","volume":"51","author":"Dreyling","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2019111809151810300_B23","first-page":"355","article-title":"mdm-2 oncoprotein expression associated with deletion of the long arm of chromosome 12 in a case of mantle cell lymphoma with blastoid transformation [corrected].","volume":"9","author":"Haidar","year":"1996","journal-title":"Mod Pathol"},{"issue":"11","key":"2019111809151810300_B24","first-page":"1010","article-title":"Oncoprotein MDM2 overexpression is associated with poor prognosis in distinct non-Hodgkin's lymphoma entities.","volume":"12","author":"M\u00f8ller","year":"1999","journal-title":"Mod Pathol"},{"issue":"11","key":"2019111809151810300_B25","first-page":"1141","article-title":"p53 and mdm2 in mantle cell lymphoma in leukemic phase.","volume":"87","author":"Solenthaler","year":"2002","journal-title":"Haematologica"},{"issue":"6","key":"2019111809151810300_B26","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1158\/0008-5472.CAN-04-1526","article-title":"CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a\/ARF locus.","volume":"65","author":"Hern\u00e1ndez","year":"2005","journal-title":"Cancer Res"},{"issue":"7","key":"2019111809151810300_B27","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1073\/pnas.0510441103","article-title":"Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma.","volume":"103","author":"Greiner","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2019111809151810300_B28","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3324\/haematol.10891","article-title":"Increased MDM2 expression is associated with inferior survival in mantle-cell lymphoma, but not related to the MDM2 SNP309.","volume":"92","author":"Hartmann","year":"2007","journal-title":"Haematologica"},{"issue":"17","key":"2019111809151810300_B29","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1038\/sj.onc.1208615","article-title":"The p53 pathway: positive and negative feedback loops.","volume":"24","author":"Harris","year":"2005","journal-title":"Oncogene"},{"issue":"17","key":"2019111809151810300_B30","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.1158\/1078-0432.CCR-08-0150","article-title":"Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage-independent p53 phosphorylation in mantle cell lymphoma.","volume":"14","author":"Jones","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2019111809151810300_B31","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1158\/1078-0432.CCR-08-0399","article-title":"MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma.","volume":"15","author":"Tabe","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2019111809151810300_B32","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/leu.2008.348","article-title":"Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma.","volume":"23","author":"Drakos","year":"2009","journal-title":"Leukemia"},{"issue":"2","key":"2019111809151810300_B33","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.canlet.2010.08.015","article-title":"MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma.","volume":"299","author":"Jin","year":"2010","journal-title":"Cancer Lett"},{"issue":"11","key":"2019111809151810300_B34","doi-asserted-by":"crossref","first-page":"8317","DOI":"10.1074\/jbc.M608667200","article-title":"Epstein-Barr virus lytic infection induces retinoic acid-responsive genes through induction of a retinol-metabolizing enzyme, DHRS9.","volume":"282","author":"Jones","year":"2007","journal-title":"J Biol Chem"},{"issue":"9","key":"2019111809151810300_B35","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"key":"2019111809151810300_B36","first-page":"61","article-title":"The median-effect principle and the combination index for quantitation of synergism and antagonism.","volume-title":"Synergism and antagonism in chemotherapy","author":"Chou","year":"1991"},{"key":"2019111809151810300_B37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"issue":"6773","key":"2019111809151810300_B38","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/35003506","article-title":"A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage.","volume":"404","author":"Tanaka","year":"2000","journal-title":"Nature"},{"issue":"16","key":"2019111809151810300_B39","doi-asserted-by":"crossref","first-page":"9114","DOI":"10.1016\/S0021-9258(17)39337-7","article-title":"Cell cycle-dependent expression of mammalian ribonucleotide reductase. Differential regulation of the two subunits.","volume":"260","author":"Engstr\u00f6m","year":"1985","journal-title":"J Biol Chem"},{"issue":"23","key":"2019111809151810300_B40","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1021\/bi00475a007","article-title":"S-phase-specific expression of mammalian ribonucleotide reductase R1 and R2 subunit mRNAs.","volume":"29","author":"Bj\u00f6rklund","year":"1990","journal-title":"Biochemistry"},{"issue":"24","key":"2019111809151810300_B41","first-page":"8723","article-title":"Interaction of p53 and DNA-PK in response to nucleoside analogues: potential role as a sensor complex for DNA damage.","volume":"61","author":"Achanta","year":"2001","journal-title":"Cancer Res"},{"issue":"10","key":"2019111809151810300_B42","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1073\/pnas.0708917105","article-title":"Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition.","volume":"105","author":"Shangary","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2019111809151810300_B43","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3816\/CLML.2010.n.066","article-title":"Management of mantle cell lymphoma: key challenges and next steps.","volume":"10","author":"Williams","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2019111809151810300_B44","article-title":"Mantle cell lymphoma: the promise of new treatment options [published online ahead of print December 16, 2010].","author":"Goy","journal-title":"Crit Rev Oncol Hematol"},{"issue":"18","key":"2019111809151810300_B45","first-page":"5151","article-title":"Ribonucleotide reductase M1 subunit in cellular proliferation, quiescence, and differentiation.","volume":"48","author":"Mann","year":"1988","journal-title":"Cancer Res"},{"issue":"19","key":"2019111809151810300_B46","doi-asserted-by":"crossref","first-page":"11695","DOI":"10.1016\/S0021-9258(20)71265-2","article-title":"Cell cycle-dependent regulation of mammalian ribonucleotide reductase. The S phase-correlated increase in subunit M2 is regulated by de novo protein synthesis.","volume":"259","author":"Eriksson","year":"1984","journal-title":"J Biol Chem"},{"issue":"10","key":"2019111809151810300_B47","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/sj.bjc.6604344","article-title":"Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel\/gemcitabine.","volume":"98","author":"Souglakos","year":"2008","journal-title":"Br J Cancer"},{"issue":"9","key":"2019111809151810300_B48","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1038\/sj.leu.2402579","article-title":"Mechanisms of resistance to nucleoside analogue chemotherapy in mantle cell lymphoma: a molecular case study.","volume":"16","author":"Reiman","year":"2002","journal-title":"Leukemia"},{"issue":"55","key":"2019111809151810300_B49","doi-asserted-by":"crossref","first-page":"8941","DOI":"10.1038\/sj.onc.1208084","article-title":"Activation of mitochondrial apoptotic pathway in mantle cell lymphoma: high sensitivity to mitoxantrone in cases with functional DNA-damage response genes.","volume":"23","author":"Ferrer","year":"2004","journal-title":"Oncogene"},{"key":"2019111809151810300_B50","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.657.657","article-title":"A multicenter, open-label, phase I study of single Agent RG7112, a first in class p53-MDM2 antagonist, in patients with relapsed\/refractory acute myeloid and lymphoid leukemias (AML\/ALL) and refractory chronic lymphocytic leukemia\/small cell lymphocytic lymphomas (CLL\/SCLL) [abstract].","volume":"116","author":"Andreeff","year":"2010","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/15\/4140\/1342162\/zh804111004140.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/15\/4140\/1342162\/zh804111004140.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T16:57:40Z","timestamp":1741453060000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/15\/4140\/29043\/HDM2-inhibition-suppresses-expression-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,13]]},"references-count":50,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2011,10,13]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-03-340323","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,13]]}}}